Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 37, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s13046-018-0704-8
Keywords
Acute myeloid leukemia; CDK9 inhibitor; Positive transcription elongation factor b; P-TEFb; MCL-1; MYC
Categories
Funding
- Boston Biomedical, Cambridge, MA
Ask authors/readers for more resources
Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available